IP Library Granted Patent US 9,527,813
Granted Patent B2
US 9,527,813 · App. 13/945,605 · Granted Dec 27, 2016

Process for the synthesis of (+) and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane

Inventors: Jerry A. Murry (Newbury Park, CA); Edward G. Corley (Freehold, NJ); Feng Xu (Staten Island, NY); Bryon Simmons (Princeton, NJ)
Assignee: EUTHYMICS BIOSCIENCE, INC.
C07D209/52C07C211/29C07C215/38C07C255/46
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,527,813
App. No.
13/945,605
Granted
Dec 27, 2016
Kind
B2
Abstract

The present invention is concerned with novel processes for the preparation of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. These compounds have pharmaceutical utility and are known to be useful for treating e.g., depression, anxiety disorders, eating disorders and urinary incontinence.

Claims (31)

1. A process for preparing a compound of the formula I:

or a pharmaceutically acceptable salt thereof, comprising:

contacting 3,4-dichlorophenylacetonitrile and (S)-epichlorohydrin of the formula:

in the presence of a base, to give cyclopropyl compounds of the formula II:

followed by reducing the compounds of formula II with a reducing agent to give amino alcohol compounds of the formula III:

followed by chlorinating the compounds of formula III with a chlorinating agent to give chloro compounds of the formula IV:

followed by cyclodehydration of the compounds of the formula IV with a base to give the compound of formula I, or a pharmaceutically acceptable salt thereof.

2. A process for preparing a compound of the formula I:

or a pharmaceutically acceptable salt thereof, comprising:

cyclodehydration of the compound of the formula IV-I:

with a base to give the compound of formula I, or a pharmaceutically acceptable salt thereof.

3. The process of claim 1 wherein the step of contacting 3,4-dichlorophenyl-acetonitrile and (S)-epichlorohydrin in the presence of a base to give cyclopropyl compounds of the formula II, the base is selected from sodium hexamethyldisilazide (NaHMDS), potassium hexamethyldisilazide (KHMDS), lithium hexamethyldisilazide (LiHMDS), potassium t-butoxide, potassium t-pentoxide, potassium amylate, lithium diisopropylamide (LDA), lithium tetramethylpiperidide (LiTMP), sec-butyllithium, and tert-butyllithium.

4. The process of claim 3 wherein the base is selected from sodium hexamethyldisilazide (NaHMDS), potassium hexamethyldisilazide (KHMDS) and lithium hexamethyldisilazide (LiHMDS).

5. The process of claim 4 wherein the base is sodium hexamethyldisilazide (NaHMDS).

6. The process of claim 1 wherein the step of reducing of the compounds of the formula II with a reducing agent to give amino alcohol compounds of the formula III, the reducing agent is selected from borane dimethyl sulfide complex, borane tetrahydrofuran complex, sodium borohydride-borontrifluoride etherate, a dialkylborane, 9-borabicyclo[3.3.1]-nonane (9-BBN), and lithium aluminum hydride (LAH).

7. The process of claim 6 wherein the reducing agent is borane dimethyl sulfide complex.

8. The process of claim 1 wherein the step of chlorinating the compounds of the formula III with a chlorinating agent to give chloro compounds of the formula IV, the chlorinating agent is selected from thionyl chloride, SO 2 Cl 2 , and Ph 3 P/CCl 4 .

9. The process of claim 8 wherein the chlorinating agent is thionyl chloride.

10. The process of claim 1 wherein the step of cyclodehydration of the compounds of the formula IV with a base to give the compound of formula I, the base is selected from sodium hydroxide, potassium hydroxide, potassium bicarbonate, sodium bicarbonate, potassium carbonate, sodium carbonate, Et 3 N, i-Pr 2 NEt, DABCO and DBU.

11. The process of claim 10 wherein the base is sodium hydroxide.

12. The process of claim 1 wherein the steps are conducted sequentially without isolation of the compounds of formula II, formula III, or formula IV.

13. The process of claim 1 , further comprising isolating the compound of formula I or a pharmaceutically acceptable salt thereof.

14. The process of claim 1 , further comprising isolating a pharmaceutically acceptable salt of formula I.

15. The process of claim 2 , further comprising isolating the compound of formula I or a pharmaceutically acceptable salt thereof.

16. The process of claim 2 , further comprising isolating a pharmaceutically acceptable salt of formula I.

17. The process of claim 2 , wherein the compound of the formula IV-I is prepared by chlorinating compounds of formula III:

with a chlorinating agent.

18. A compound which is selected from the group consisting of:

or a salt thereof.

19. A compound which is selected from the group consisting of:

or a salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2018
From: EUTHYMICS BIOSCIENCE, INC.
To: ETHISMOS RESEARCH, INC.
Reel/Frame 045252/0870 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2014
From: MURRY, JERRY A.; SIMMONS, BRYON; CORLEY, EDWARD G.; XU, FENG
To: MERCK & CO., INC.
Reel/Frame 032761/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 25, 2014
From: MERCK & CO., INC.
To: DOV PHARMACEUTICAL, INC.
Reel/Frame 032761/0137 →
CHANGE OF NAME Recorded Apr 25, 2014
From: DOV PHARMACEUTICAL, INC.
To: EUTHYMICS BIOSCIENCE, INC.
Reel/Frame 032761/0432 →
Continuity (6)
Continuation 13366211 · Feb 3, 2012
Continuation 13207279 · Aug 10, 2011
Continuation 12782705 · May 18, 2010
Continuation 11740667 · Apr 26, 2007
Provisional Application 60796097 · Apr 28, 2006
Related Publication 20140163240A1 · Jun 12, 2014